Following a two-month transition, Paul Pomerantz, MBA, CAE, officially has begun his work as the new worldwide executive director of the Drug Information Association (DIA).
Horsham, PA, USA (Vocus) December 4, 2009 -- Following a two-month transition, Paul Pomerantz, MBA, CAE, officially has begun his work as the new worldwide executive director of the Drug Information Association (DIA). Pomerantz was previously the executive vice president of the American Society of Plastic Surgeons (ASPS). He replaces William Brassington, MBA, who has served as DIA’s acting executive director since July 2008. Brassington will resume his role as DIA worldwide director of finance.
“As part of my transition, I was extremely fortunate to be able to contribute to the board of director’s strategic planning regarding an expanded vision and mission for DIA,” said Pomerantz. “Those conversations are critical at this moment because of the rapidly changing global healthcare landscape. Our job is to ensure that our programming remains relevant and meaningful for our members and volunteers, and I am confident that our long-term strategic plan and revised mission and vision will allow us to collectively make an impact on improving healthcare worldwide.”
Most significantly, the new DIA vision and mission raises the association’s role from a neutral venue for sharing best practices to one that facilitates the knowledge that is needed to raise the level of health and well being worldwide. Pomerantz is charged with ensuring that the essence of the new vision and mission statements are incorporated into all aspects of DIA’s educational programming and operations. Along with that, Paul is responsible for directing DIA’s global operations and strategic expansion and for leading the implementation of the board of director’s long-term plan for sustainability and growth.
Pomerantz brings to DIA more than 30 years of executive experience with specialized expertise in health policy, medical society management, and health administration.
“It’s not often that the timing around an exciting new strategy coincides with the start of new, passionate leadership, but DIA is fortunate to have both,” said DIA Board President Jeff Sherman. “I know Paul agrees that for us to truly meet our mission, we need to build relationships with new scientific, industry, academic, patient, and regulatory stakeholders who can contribute to the value of our global, multidisciplinary, and neutral educational and networking forum. We hope that this new vision and mission will help to reinforce the work we’re doing together to raise the level of health worldwide.”
To see the complete and expanded DIA Vision and Mission Statements, please visit www.diahome.org.
About the Drug Information Association (DIA)
As a nonprofit member-driven association, DIA serves more than 30,000 professionals involved in the biopharmaceutical industry, academia, research organizations and governmental bodies worldwide. DIA fosters innovation of products, technologies, and services to improve health and well being worldwide by providing indispensible forums to exchange vital information and discuss current issues, delivering customized learning experiences, building, maintaining, and facilitating trusted relationships with and among individuals and organizations that drive and share DIA values and mandates, and providing a multidisciplinary neutral environment, respected globally for integrity and relevancy. DIA is led by its volunteer Board of Directors and executive management team, has headquarters in Horsham, PA, USA, and offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China. For more information, visit www.diahome.org or call 215-442-6100.
Devine + Powers
Devine + Powers
Read the full story at http://www.prweb.com/releases/2009/12/prweb3299424.htm.
Copyright©2009 Vocus, Inc.
All rights reserved